IBDEI0UR ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14942,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14942,1,4,0)
 ;;=4^796.2
 ;;^UTILITY(U,$J,358.3,14942,1,5,0)
 ;;=5^Elev BP w/o dx hypertension
 ;;^UTILITY(U,$J,358.3,14942,2)
 ;;=^273464
 ;;^UTILITY(U,$J,358.3,14943,0)
 ;;=402.10^^81^936^31
 ;;^UTILITY(U,$J,358.3,14943,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14943,1,4,0)
 ;;=4^402.10
 ;;^UTILITY(U,$J,358.3,14943,1,5,0)
 ;;=5^HTN w/ Heart Involvement
 ;;^UTILITY(U,$J,358.3,14943,2)
 ;;=^269598
 ;;^UTILITY(U,$J,358.3,14944,0)
 ;;=402.11^^81^936^32
 ;;^UTILITY(U,$J,358.3,14944,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14944,1,4,0)
 ;;=4^402.11
 ;;^UTILITY(U,$J,358.3,14944,1,5,0)
 ;;=5^HTN with CHF
 ;;^UTILITY(U,$J,358.3,14944,2)
 ;;=HTN with CHF^269599
 ;;^UTILITY(U,$J,358.3,14945,0)
 ;;=403.11^^81^936^37
 ;;^UTILITY(U,$J,358.3,14945,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14945,1,4,0)
 ;;=4^403.11
 ;;^UTILITY(U,$J,358.3,14945,1,5,0)
 ;;=5^HTN with Renal Failure
 ;;^UTILITY(U,$J,358.3,14945,2)
 ;;=^269608
 ;;^UTILITY(U,$J,358.3,14946,0)
 ;;=404.10^^81^936^35
 ;;^UTILITY(U,$J,358.3,14946,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14946,1,4,0)
 ;;=4^404.10
 ;;^UTILITY(U,$J,358.3,14946,1,5,0)
 ;;=5^HTN with Heart & Renal Involvement
 ;;^UTILITY(U,$J,358.3,14946,2)
 ;;=^269618
 ;;^UTILITY(U,$J,358.3,14947,0)
 ;;=404.11^^81^936^33
 ;;^UTILITY(U,$J,358.3,14947,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14947,1,4,0)
 ;;=4^404.11
 ;;^UTILITY(U,$J,358.3,14947,1,5,0)
 ;;=5^HTN with CHF & Renal Involvement
 ;;^UTILITY(U,$J,358.3,14947,2)
 ;;=^269619
 ;;^UTILITY(U,$J,358.3,14948,0)
 ;;=404.12^^81^936^36
 ;;^UTILITY(U,$J,358.3,14948,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14948,1,4,0)
 ;;=4^404.12
 ;;^UTILITY(U,$J,358.3,14948,1,5,0)
 ;;=5^HTN with Heart Involvement & Renal Failure
 ;;^UTILITY(U,$J,358.3,14948,2)
 ;;=^269620
 ;;^UTILITY(U,$J,358.3,14949,0)
 ;;=404.13^^81^936^34
 ;;^UTILITY(U,$J,358.3,14949,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14949,1,4,0)
 ;;=4^404.13
 ;;^UTILITY(U,$J,358.3,14949,1,5,0)
 ;;=5^HTN with CHF & Renal failure
 ;;^UTILITY(U,$J,358.3,14949,2)
 ;;=^269621
 ;;^UTILITY(U,$J,358.3,14950,0)
 ;;=401.9^^81^936^57
 ;;^UTILITY(U,$J,358.3,14950,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14950,1,4,0)
 ;;=4^401.9
 ;;^UTILITY(U,$J,358.3,14950,1,5,0)
 ;;=5^Hypertension, Essential
 ;;^UTILITY(U,$J,358.3,14950,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,14951,0)
 ;;=272.0^^81^936^55
 ;;^UTILITY(U,$J,358.3,14951,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14951,1,4,0)
 ;;=4^272.0
 ;;^UTILITY(U,$J,358.3,14951,1,5,0)
 ;;=5^Hypercholesterolemia, Pure
 ;;^UTILITY(U,$J,358.3,14951,2)
 ;;=^59973
 ;;^UTILITY(U,$J,358.3,14952,0)
 ;;=272.1^^81^936^58
 ;;^UTILITY(U,$J,358.3,14952,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14952,1,4,0)
 ;;=4^272.1
 ;;^UTILITY(U,$J,358.3,14952,1,5,0)
 ;;=5^Hypertriglyceridemia
 ;;^UTILITY(U,$J,358.3,14952,2)
 ;;=Hypertriglyceridemia^101303
 ;;^UTILITY(U,$J,358.3,14953,0)
 ;;=272.2^^81^936^63
 ;;^UTILITY(U,$J,358.3,14953,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14953,1,4,0)
 ;;=4^272.2
 ;;^UTILITY(U,$J,358.3,14953,1,5,0)
 ;;=5^Mixed Hyperlipidemia
 ;;^UTILITY(U,$J,358.3,14953,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,14954,0)
 ;;=396.0^^81^936^11
 ;;^UTILITY(U,$J,358.3,14954,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14954,1,4,0)
 ;;=4^396.0
 ;;^UTILITY(U,$J,358.3,14954,1,5,0)
 ;;=5^Aortic and Mitral Stenosis
 ;;^UTILITY(U,$J,358.3,14954,2)
 ;;=Aortic and Mitral Stenosis^269580
 ;;^UTILITY(U,$J,358.3,14955,0)
 ;;=414.02^^81^936^18
 ;;^UTILITY(U,$J,358.3,14955,1,0)
 ;;=^358.31IA^5^2
 ;;
 ;;$END ROU IBDEI0UR
